1	Long-term air pollut	ion, cardiometabolic multimorbidity, and genetic
2	susceptibility: a mul	ti-state modeling study of 415,855 participants
3		
4	Xu Gao ^{1#} , Meijie Jiang ^{1#}	, Ninghao Huang ² , Xinbiao Guo ¹ , Andrea A. Baccarelli ³ , Tao Huang ²
5		
6	¹ Department of Occupati	onal and Environmental Health Sciences, School of Public Health, Peking
7	University.	
8	² Department of Epidemio	logy and Biostatistics, School of Public Health, Peking University, Beijing,
9	China	
10	³ Laboratory of Environme	ental Precision Health, Mailman School of Public Health, Columbia
11	University, New York, N	Y, USA
12		
13	#Contributed to the study	equally
14		
15	Corresponding author:	Xu Gao, Ph.D.
16		Department of Occupational and Environmental Health Sciences
17		School of Public Health, Peking University
18		No.38 Xueyuan Road, Haidian District
19		Beijing, China 100191
20		Phone: +86-136-2190-8907
21		Email: <u>xu.gao@pku.edu.cn</u>
22		ORCID: https://orcid.org/0000-0001-6506-6084

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved. N	o reuse allowed without	permission.
------------------------	-------------------------	-------------

23	Abstract
24	Background: Cardiometabolic multimorbidity (CMM) with at least two cardiometabolic diseases
25	(CMDs) including type II diabetes (T2D), ischemic heart disease (IHD), and stroke, is a global health
26	problem with multiplicative mortality risk and deserves to be investigated as a top priority. Although
27	air pollution is a leading modifiable environmental risk for individual CMD, its impacts on CMM
28	progression were poorly understood.
29	Objective: To elucidate the impact of air pollution on CMM progression, individually and in the
30	context of genetic preposition.
31	Design: Multi-state modeling cohort study.
32	Setting: Data were extracted from the UK Biobank.
33	Participants: 415,855 eligible UK Biobank adults that were free of CMDs at baseline.
34	Measurements: Annual concentrations of particulate matter (PM) with a diameter of $\leq 2.5 \ \mu m$
35	(PM _{2.5}), 2.5-10 μ m (PM _{2.5-10}), and \leq 10 μ m (PM ₁₀), and nitrogen oxides (NO _x and NO ₂) were
36	estimated using Land Use Regression model.
37	Results: During a median follow-up of 8.93 years, 33,375 participants had a first CMD (FCMD),
38	and 3,257 subsequently developed CMM. PM2.5, PM10, NO2, and NOx levels, as well as their
39	combined exposure were associated with increased FCMD risks and even higher risks of CMM.
40	Particularly, per a $5-\mu g/m^3$ increase in PM _{2.5} , risks for FCMD and CMM increased by 27% (95%)
41	confidence interval: 20%-34%) and 41% (18%-68%), respectively. By FCMD types, participants
42	with IHD had a higher risk of CMM than those with T2D or stroke. Eighty-five CMD-related genetic
43	variants were associated with CMM trajectories in our study and associations of air pollution with
44	FCMD and CMM risks could be aggravated progressively with increasing genetic risks.

- 45 Limitations: Other major air pollutants including ozone and SO₂ were not considered due to the data
- 46 availability.
- 47 **Conclusions:** Air pollution has profound adverse health impacts on the progression of CMM through
- 48 multi-stage dynamics, especially for individuals with IHD and high genetic risk.

49

Introduction

50	Multimorbidity is defined as the simultaneous presence of two or more chronic diseases and is an
51	increasing global health problem with impaired quality of life, reduced life expectancy, and elevated
52	cost of health care resources by a larger scale than any chronic conditions individually (1).
53	Cardiometabolic multimorbidity (CMM), as one of the most common multimorbidity patterns (2),
54	refers to the coexistence of two or three most prevalent cardiometabolic diseases (CMDs), including
55	type II diabetes (T2D), ischemic heart disease (IHD), and stroke (2, 3). A study based on 91 cohorts
56	identified that any combination of these CMDs was associated with multiplicative mortality risk, and
57	life expectancy was substantially lower in people with CMM with a reduction of life expectancy up
58	to 15 years (3). CMM, therefore, is not simply an accumulation of the three healthy conditions but
59	rather a collision of risk factors promoting death. Up to date, there is a dearth of studies on the
60	determinants of CMM, which is urgently needed to seek appropriate management approaches to
61	early prevent and control CMM development (4).
62	
63	Ambient air pollution, especially fine particulate matter (PM _{2.5} , aerodynamic diameter $<2.5 \ \mu$ m), has
64	been recognized as a modifiable risk factor for CMDs (5, 6). For instance, a meta-analysis identified
65	a robust positive association between PM exposure and the incidence of T2D (7). Petal et al. also
66	reported that a 10 μ g/m ³ increase in PM _{2.5} and particulate matter (PM) of sizes 10 μ m (PM ₁₀) was
67	associated with 0.25% higher IHD mortality and 0.27% higher IHD morbidity (8). Short-term air
68	pollution exposure could also increase the daily hospital admissions for ischemic stroke (9).
69	Understanding the impact of air pollution on the dynamics of CMM thereby could hint targeted
70	population of CMM prevention. Nevertheless, this is not sufficient to depict the risks of CMM

71	coming from air pollution exposure without accounting for the temporal development of CMM using
72	traditional time-to-event analyses. Additionally, CMDs have been suggested to be affected mutually
73	by environmental exposures and genetic profiles (10), but knowledge on whether the genetic
74	predisposition of CMM and air pollution could jointly promote the CMM development remains
75	unknown.
76	
77	Therefore, we aimed to investigate the associations of five pollutants (PM2.5, PM2.5-10, PM10, NO2,
78	and NOx) with the CMM trajectories using the scheme of multi-state modeling in the UK Biobank.
79	The multi-state model could evaluate the risk of five transient states (baseline CMD-free to first
80	CMD [FCMD], baseline to death, FCMD to CMM, FCMD to death, and CMM to death) on
81	occupying another state (11). Leveraging in-depth genetic information, this study additionally
82	allowed us to explore the potential synergetic effect of genetic profile and air pollution on CMM.

0	2
o	J
_	_

Methods

84 Study design and participants

- 85 UK Biobank is a large population-based prospective cohort study (12). As previously described,
- about 0.5 million UK residents aged 37-73 years were enrolled from 2006-2010, and the end date of
- 87 follow-up was 31 December 2018. Their information collected includes lifestyle and health data,
- 88 physical measurements, and biological samples. After excluding participants without information on
- 89 air pollution, CMDs, and selected covariates, and those with T2D, IHD, and stroke at baseline, a total
- 90 of 415,855 participants without diagnosis of the three CMDs were included in our study for further
- 91 analyses to exclude the impact of baseline CMD on the association between air pollution and CMM
- 92 trajectories (Figure S1). The UK Biobank was approved by the North West Multicenter Research
- 93 Ethical Committee. All participants provided informed written consent. This research has been
- 94 conducted using the UK Biobank Resource under Application Number 44430.
- 95

96 Cardiometabolic diseases and mortality

97 Incident IHD, stroke, and T2D cases, as well as relevant mortality, were retrieved from primary care
98 and hospital admission data using the UK National Health Services register. We used the

and nospital admission data using the OK trational freaturi services register. We used the

99 International Classification of Diseases 10th revision (ICD-10) and primary care health records to

100 identify relevant diagnoses. IHD was defined by codes I20 to I25. Stroke was defined by codes I60

- to I69. T2D was diagnosed based on the following criteria: having fasting glucose \geq 7.0 mmol/L or 2-
- hour plasma glucose ≥ 11.1 mmol/L, having physician-diagnosed diabetes, using diabetes medication,
- 103 or with ICD-10 code E11.
- 104

105 *Exposure assessments*

106	Annual 1-year moving average ambient concentrations of PM _{2.5} , PM _{2.5-10} , PM ₁₀ , NO ₂ , and NO _x were
107	calculated with a Land Use Regression (LUR) model. Details about the LUR model are in the
108	supplement methods. Previous reports using leave-one-out cross-validation demonstrated good
109	model performance for PM _{2.5} , PM ₁₀ , NO ₂ and NO _x (R^2 of cross-validation =77%, 88%, 87% and
110	88%, respectively) and a moderate performance for PM_{coarse} (cross-validation R^2 =57%).
111	Concentrations of PM _{2.5} , PM _{2.5-10} , and NO _x were available in 2010 only, while concentrations of
112	PM_{10} (2007 and 2010) and NO_2 (2005, 2006, 2007, and 2010) were collected for multiple years.
113	Since the baseline enrollment was conducted from 2006 to 2010, to better fit the time frame of
114	baseline survey, we used averaged levels of PM ₁₀ and NO ₂ in this study.
115	
116	To explore the combined impact of air pollutants, we weighted the levels of PM _{2.5} , PM ₁₀ , NO _x , and
117	NO ₂ using the β coefficients retrieved from the transition process from baseline to FCMD based on
118	Cox regression models adjusting for all covariates described below. PM _{2.5-10} was removed due to its
119	null associations with CMDs (see the Result section for details). This approach was validated in a
120	10-fold cross-validation analysis in a previous air pollution-related study based on UK Biobank (13,
121	14). Weighted indicator (termed as "co-exposure score") was estimated as: co-exposure score =
122	$(\beta_{PM2.5}] \times PM_{2.5} + \beta_{PM10} \times PM_{10} + \beta_{PN02} \times NO_2 + \beta_{PN0x} \times NO_x) \times (4/\text{sum of the } \beta \text{ coefficients}).$
123	The co-exposure score ranged from 36.50 to 141.78. Participants were divided into five groups based
124	on the quintiles.
125	

126 Genetic information and genetic risk scores

127	Detailed information about genotyping, imputation, and quality control in UK Biobank has been
128	described previously (15) and provide in supplement methods. Based on previous genome-wide
129	association studies (GWASs) (16-18), we retrieved 74 single-nucleotide polymorphisms (SNPs) for
130	T2D, 55 for IHD, and 32 for stroke (Table S1). We first coded each SNP as 0 and 1 according to the
131	existence of risk alleles to test their independent associations with CMM using MSM and then
132	selected 85 SNPs that were nominal significantly related to any processes of CMM development (see
133	the Result section for details) to create a weighted genetic risk score (GRS). Each selected SNP was
134	then recoded as 0, 1, or 2 according to the number of risk alleles, and multiplied by the logarithmic
135	odds ratios (ORs) obtained from the previous GWAS to calculate the GRS as previously described
136	(19). The GRS ranged from 57.4 to 117.9, with a higher score indicating a higher genetic risk of
137	CMM.

138

139 Covariates

As previously reported (20), the following potential covariates were retrieved from the baseline 140 questionnaires and physical examinations, including age, sex (male/female), body mass index (BMI), 141 years of education (<10 years/ \geq 10 years), race (based on UK Biobank question "self-reported ethnic 142 group", categorized into White, Black, Asian, and other; other included those reported "white and 143 144 black mixed" and "other ethnic group" to the question), smoking status (never, former, current), 145 employment status (employed/unemployed), total household income (≥£31000/ <£31000), moderate alcohol intake status (yes/no), and high-level physical activity status (yes/no). Detailed measures of 146 the covariates were described in supplement methods. 147

148

149 Statistical analysis

150	Survival time for each participant was calculated as the duration from the response date of baseline
151	to the date of incident, death, or date of censoring, whichever came first. We first used Cox
152	regression to examine the associations of five pollutants with FCMD, CMM, and death, separately.
153	Proportional hazard assumptions were not violated based on the Schoenfeld residuals test. Previously
154	described covariates were adjusted in the models. We then used the unidirectional multi-state model
155	(MSM) to assess five pollutants in the temporal disease development from free of CMDs to FCMD,
156	CMM, and death. The MSM was carried out with Markov proportional hazards (21, 22), which is an
157	extension of competing risks survival analysis allowing estimation of the role of a certain factor in
158	different phases of a process. If a participant was recorded with at least two events (CMDs and/or
159	death) at the same time point simultaneously, we theoretically assumed that the order of disease
160	occurrence was T2D, IHD, and stroke according to previous evidence (3, 23, 24), and died
161	eventually. Times for the previous disease were accordingly minus 0.5 days.
162	
163	First, five transition processes were constructed according to the natural history of CMM and
164	previous studies (24, 25) (transition pattern A, Figure 1): (I) from baseline to FCMD; (II) from
165	baseline to death from a disease other than T2D, IHD, and stroke; (III) from FCMD to CMM; (IV)
166	from FCMD to death from any causes; and (V) from CMM to death from any causes. Processes I,
167	III, and V were the primary ones with the most interest of study in our analysis. Then, to explore
168	which CMD was associated with higher risks of CMM, we further used the MSMs to analyze the
169	effects of air pollutants on different pathways from baseline to CMM by dividing the FCMDs into
170	T2D, IHD, and stroke separately. Thus, along with processes II and V of pattern A, the processes I,

171	III, and IV of pattern A were further divided into nine sub-transitions (Ia-Ic; IIIa-IIIc, IVa-IVc) in
172	pattern B (transition pattern B, Figure 1). Restricted cubic spline regression models were then used to
173	evaluate the dose-response relationship between air pollutants and each CMM processes with 3
174	knots (10 th , 50 th , and 90 th percentiles of exposures).
175	
176	To clarify the effects of genetic susceptibility and air pollution on CMM, we tested the gene-air
177	pollution interaction first using the MSM with an interaction term of the continuous co-exposure
178	score and CMM-related SNPs and continuous GRS to examine the potential modifying effect of
179	genetic background. In the case that interaction effect did not meet criteria for statistical significance
180	(p-values<0.05), we generated a series of categorical variable based on the quintiles of co-exposure
181	score and binary GRS (by median) to assess their joint effects on CMM development.

182

Six sensitivity analyses were conducted to validate the robustness of our findings. First, we 183 constructed another weighted co-exposure score based on PM2.5, NO2, and NOx to understand 184 whether the marginal association of PM₁₀ with CMM may distort the findings towards null. Then we 185 conducted the MSM of pattern A by adjusting for baseline diet behavior, and levels of low-density 186 lipoprotein, high-density lipoprotein, triglycerides, total cholesterol, systolic blood pressure, and 187 188 diastolic blood pressure, all of which were established to be related to CMD and their subsequent outcomes (26). Furthermore, we conducted the MSM of pattern A by adjusting for ten genetic 189 190 principal components of UK Biobank and also in the white participants only to ensure the reliability of our findings across different ethnicities. To understand the impact of mobilization on our findings, 191 192 we additionally conducted the MSM of pattern A in participants who self-reported that he/she had

- been living at the same baseline address for more than five years. Last, we evaluated whether the age
- 194 at FCMD onset (<65 years or \geq 65 years) could modify the association between air pollution and
- 195 subsequent CMM.
- 196
- 197 All analyses were conducted using R (version 4.0.1). MSM was performed using "mstate" package
- 198 of R. A two-tailed *p*-value <0.05 indicated statistical significance.

Results

200 Descriptive analysis

- 201 Detailed characteristics of the eligible 415,855 participants are shown in Table S2. The mean \pm
- standard deviation (SD) age at baseline was 56.23±8.09 years. Most participants (94.83%) were
- white. Nearly half of the participants were former or never smokers with moderate alcohol intake,
- and had a total household income $\geq \pounds 31,000$. During a median follow-up of 8.93 years, a total of
- 205 33,375 participants (8.03%) experienced FCMD. Among them, about half experienced IHD
- 206 (N=16,385), 13,533 experienced T2D, and 3,007 experienced strokes (Figure 1). The mean (SD)
- ambient levels of PM_{2.5}, PM_{2.5-10}, PM₁₀, NO₂, and NO_x were 9.97 (1.05), 6.42 (0.90), 19.28 (1.95),
- 208 29.08 (9.21), and 43.74 (15.56) μ g/m³, respectively. The pollutants were mutually correlated with
- 209 each other (Figure S2, *p*-values <0.001).
- 210

211 Associations between air pollution and cardiometabolic multimorbidity

Patten A was our primary model of CMM development (Figure 1). Fully-adjusted Cox models 212 213 showed that PM_{2.5}, PM₁₀, NO₂, and NO_x were associated with the risks of FCMD, CMM, and death, respectively (Table S3). The MSM was therefore useful to uncover the underlying risks of CMM 214 215 development. Figure 2 depicted that $PM_{2.5}$, NO_2 , and NO_x were significantly associated with all 216 CMM processes except for CMM-death. PM₁₀ was marginally related to baseline-FCMD and subsequently to CMM. The risk estimates of the four air pollutants were much higher for FCMD-217 CMM or FCMD-death than for baseline-FCMD. For instance, per 5-µg/m³ increment, PM_{2.5} was 218 219 associated with 27% higher risk of the whole population to develop FCMD from baseline (95% 220 confidence intervals [CIs]: 20%-34%), 41% higher risk of individuals with FCMD to progress from

221	FCMD to CMM (95% CI: 18%-68%), and 35% higher risk of individuals with FCMD to progress
222	from FCMD to death (95% CI: 11%-63%). Same increases in NO_x and NO_2 demonstrated similar
223	significant magnitudes but with reduced estimates. PM2.5-10 had null associations with all CMM
224	processes. Monotonic increasing dose-response relationships were observed for the associations of
225	PM2.5, NOx, and NO2 with the processes of baseline-FCMD, FCMD-CMM, and FCMD-death
226	(Figures 3 & S3).

227

220 Sholig associations between the co-exposure score based on 1 M _{2.5} , 1 M ₁₀ , 100x, and 1002 and 1	28	Strong associations	between the co-exposur	re score based on PM _{2.5} .	, PM_{10} , NO_x , and NO_2 and the
--	----	---------------------	------------------------	---------------------------------------	---

229 CMM processes were also observed, except for CMM-death (Figures 2 & S3-S4). Compared to the

230 1st quintile of the co-exposure score, the 5th quintile was associated with 14% (95% CI: 10%-18%),

231 22% (95% CI: 7%-38%), and 22% (95% CI: 7%-40%) higher risks for processes of baseline-FCMD,

232 FCMD-CMM, and FCMD-death, respectively. A sensitivity analysis using the modified co-exposure

score based on PM_{2.5}, NO₂, and NO_x also yielded similar estimates (Table S4).

234

235	In transition	pattern B v	which o	classified	FCMDs	into thre	e CMDs	(Figure	1),	we	found	baseli	ine
-----	---------------	-------------	---------	------------	-------	-----------	--------	---------	-----	----	-------	--------	-----

participants were more likely to initially develop T2D than IHD or stroke (Tables S5 & S6).

237 However, FCMD participants with IHD were more likely to develop CMM than those with T2D or

stroke in response to PM_{2.5}, NO₂, NO_x, and the co-exposure score (Table 1). For instance, per a 5-

 $\mu g/m^3$ increase in PM_{2.5}, the corresponding hazard ratios (HRs) of CMM were 1.51 (95% CI: 1.08-

240 2.10), 1.05 (95% CI: 1.01-1.10), and 1.01 (95% CI: 0.88-1.15) for FCMD participants with IHD,

241 T2D, and stroke, respectively.

Genetic susceptibility of cardiometabolic multimorbidity and joint effects with air pollution 243 For the retrieved CMD-related SNPs, 38 T2D-related, 32 IHD-related, and 15 stroke-related loci 244 245 were nominally associated with any CMM trajectories of pattern A (Tables S1 & S7 a-c, nominal pvalues <0.05). Genes ABO, EDNRA, FURIN, MIA3, and CDKN2B-AS1 had >2 unique SNPs, and 246 247 CDKN2B-AS1 had the most including rs3217992, rs4977574, and rs7859727. The weighted GRS 248 based on these CMM-related loci was robustly associated with CMM transitions (Table S7). However, none of the SNPs or the continuous GRS could interact with the co-exposure score in 249 relation to CMM trajectories (Table S6 d-f, interaction FDR-corrected p>0.05; Table S9, interaction 250 251 *p*-values >0.1). And in the mutual adjustment model, the coefficients of GRS and the co-exposure score remained essentially unchanged compared to models with either factor (Table S9). We 252 253 suggested that the environmental and genetic factors were independently associated with CMM 254 development. 255

Given no interaction was observed, we generated a series of categorical variable based on the
quintiles of co-exposure score and dichotomized GRS (by median) to test the joint effects of both
factors. We observed gradients in associations of higher GRS and co-exposure score for the
processes of baseline-FCMD and FCMD-CMM (Figure 4). For instance, FCMD participants with the
5th quintile co-exposure score and a high GRS had a higher risk of CMM compared to those with the
1st quintile of co-exposure score and a low GRS with a HR of 1.40 (95% CI: 1.16-1.70) (Table S19).
But no significant joint effects on baseline-death, FCMD-death, or CMM-death was found.

264 Sensitivity analyses

265	In the model which further adjusted for baseline diet behavior, lipoprotein levels, and blood pressure
266	(Table S11), the estimates of $PM_{2.5}$, NO_2 , NO_x , and the co-exposure score remained essentially
267	unchanged in relation to the risks of CMM development. Results from models with additional
268	adjustment with genetic principal components (Table S12) and from models conducted in white
269	participants only (Table S13) also showed similar risks, both of which suggested the robustness of
270	our findings across the ethnicities. Similar estimates were also yielded in participants living in the
271	address for more than five years (Tables S14), suggesting that out primary results were fairly robust
272	regardless of the mobilization. Moreover, although the interactions between the age of FCMD onset
273	(<65 years or \geq 65 years) and air pollution on the CMM risks were not significant (Table S15,
274	interaction p -values >0.2), air pollution–CMM associations were stronger among the elderly aged
275	<65 years than those aged \geq 65 years.

2	7	6
-		~

Discussion

277	Utilizing the prospective data of ~0.42 million participants of the UK Biobank, we uniquely found
278	that PM2.5, NO2, and NOx levels were associated with the CMM individually and jointly as a
279	weighted co-exposure score in a multi-state nature. For participants with any FCMD, those with IHD
280	had higher risks of incident CMM and death than those who had T2D or stroke as FCMD. Risks for
281	developing FCMD and CMM under long-term air pollution could be enhanced by the CMM genetic
282	susceptibility. Our findings will help broaden the scope of public health recommendations
283	encompassing patients with CMDs and to better characterize and distinguish individuals with a high
284	risk of developing CMM under environmental insults.
285	
286	To date, there is an evident lack of studies that have specifically investigated the temporal association
287	between air pollution and CMM through methods that involve a stochastic process covering the
288	possible stages of multimorbidity rather than simply counting the numbers of non-communicable
289	diseases without considering disease-disease interactions (27). This study is the first investigation
290	showing the critical role of air pollution on the dynamics of CMM, which indicates that historical air
291	pollution exposure, especially to PM _{2.5} may have profound and lasting impacts on cardiovascular and
292	metabolic systems. In consistent with previous studies of individual CMDs (6, 7, 28), our study
293	yielded robust associations of air pollution, especially PM2.5, NO2, and NOx, with FCMD. Moreover,
294	we identified a stepwise increasing magnitude of the associations of each air pollutant with the risks
295	of CMM and death after the occurrence of FCMD. This pattern highlights the value of the secondary
296	prevention of individuals with FCMD to mitigate the additive risks of subsequent CMDs or death.
297	Additionally, although not statistically significant, individuals with a younger age at FCMD

diagnosis (<65 years) had higher CMM risk than those older. Future studies are warranted to
elucidate whether the age at FCMD onset could be recognized as a potential risk indicator of
subsequent CMM risk for the precision prevention of CMM along with environmental risk factors.

302 More intriguingly, we found that participants were more likely to develop T2D first from baseline 303 under air pollution. This may be plausible that increased blood glucose level has been recognized as a critical pathophysiology mechanism for the risks of IHD and stroke (23). We thus believed that 304 T2D could occur ahead of the onset of IHD or stroke and could be easily diagnosed in routine health 305 306 examinations. Furthermore, previous evidence implied that those with IHD or stroke could have relatively higher glucose levels or were pre-diabetic because cardiovascular events may impair 307 fasting glucose (29). Even not yet reached the diagnosis criteria of T2D, we anticipated those with 308 309 IHD or stroke to be more likely to develop T2D and CMM. However, in our study, participants with 310 IHD as FCMD showed higher risks of developing CMM or death than others who first had T2D and stroke. The attenuated risks related to stroke could be explained by better medical care of stroke 311 312 patients than those with IHD because of the sudden onset of stroke and higher mortality than IHD. Additionally, stroke patients usually receive better and systematic blood pressure and glucose 313 314 management over rehabilitation period which may considerably lower their risks of IHD, T2D, 315 and/or death (30, 31). Therefore, for areas with relatively higher stroke incidence and heavier burden of air pollution, for instance, in developing countries, CMM prevention for stroke patients may be 316 more than valuable (32). Additionally, except for the limited death numbers, null associations 317 318 between air pollution and the CMM-death process may be explained by better medical care for CMM patients. A recent study of CMM and mortality in UK general practices have demonstrated 319

that compared with people with individual CMDs, those with multimorbidity could have a higher
likelihood of receiving evidence-based treatment to lower the exceeded risk of coexisting
cardiovascular and metabolic diseases (33).

323

324	Accumulating evidence has suggested the biological pathway of CMD resulting from air pollution
325	(34), including pro-hypertension, insulin resistance, and endothelial damage resulting from oxidative
326	stress and/or inflammation, which could further promote CMM (28, 34). Beyond these common
327	etiological pathways, a recent study showed that the comorbidity of cardiovascular and metabolic
328	diseases could be explained by overlapping genetic profiles along with protein-protein interactions
329	(PPIs) as a complex network (35). In line with this, our study found that four out of the five CMM-
330	related genes (i.e., ABO, EDNRA, FURIN, and MIA3) that had ≥ 2 unique SNPs were related to
331	protein-coding and could additionally participate in PPIs of the cardiovascular network. Gene
332	CDKN2B-AS1 with the most CMM-related SNPs is not a protein-coding gene, but it produces a long
333	non-coding RNA that interacts with nearby genes and impairs the interferon- γ signaling response to
334	elevate the susceptibility of CMDs (36). Since this gene has also been related to multiple aging-
335	related diseases including cancer and glaucoma, as well as abnormalities in blood cell counts (37),
336	more work is required to uncover its role in the development of multimorbidity. Moreover,
337	insignificant interaction between air pollution and GRS was observed, but moderate additive effect
338	of genetic background on the associations of air pollution with the baseline-FCMD and FCMD-
339	CMM processes were shown. Therefore, we believe that genetic susceptibility could be considered in
340	CMM prevention in response to air pollution. Such mild clues based on SNPs reported by previous

GWAS of CMDs further suggest the identification of novel CMM-related variants is highlyrecommended to empower the risk prediction of CMM.

343

This study has several strengths including the large sample size and detailed records of CMD with 344 345 information on lifestyle and covariates that allowed us to conduct the state-of-art multi-state analysis. Several limitations should also be noted in the result interpretation. First, we only focused on the 346 CMM defined with the co-occurrence of three diseases including IHD, stoke, and T2D only because 347 this multimorbidity pattern is the most observed and studied in previous literature (2, 3). Other 348 349 important CMDs such as hyperlipidemia, and nonalcoholic fatty liver disease could be investigated in future studies. Second, UK Biobank is a volunteer cohort with participants who were likely 350 351 healthier than the general population, and we excluded those with pre-existing CMDs. Both may 352 cause selection bias influencing the effect of air pollution on CMM development towards null as relatively healthier people usually have lower risks of CMDs. Furthermore, the air pollution data was 353 mostly a single measurement of the annual average level without any further measures within a 354 355 shorter time interval. This prohibited further explorations on the lag or short-term (<1 month) influences of air pollution. Meanwhile, we did not have the data on other major air pollutants, such 356 357 as ozone and sulfur dioxide, which have been associated with CVD and T2D (38, 39) and could be studied in future multi-state investigations. Additionally, in processing the data to match the multi-358 359 state algorithm, we theoretically ascertained the occurrence orders of events if subjects have two or more events reported on the same day. This may reduce the power of MSM but very slightly because 360 361 the number of cases with such conditions was comparatively tiny (N=1192, ~3.6% of FCMD participants). Moreover, despite that we created the GRS using a GWAS of CMM based on well-362

363	established SNPs that were highly related to any CMD in previous GWASs, its generalizability in
364	predicting CMM may be required to be further validated. Last, we did not have the drug use
365	information of the participants during follow-up, which may considerably mitigate the risks of
366	subsequent adverse cardiometabolic health outcomes. Given the CMD information was mostly
367	retrieved from linkage to electronic health records, we believe that most CMD participants received
368	appropriate treatment. Such well-received CMD management may have underestimated the
369	substantial relevant detrimental impacts of air pollution on CMM development we observed.

370

Notwithstanding the improved awareness of the public on the harms of air pollution, knowledge is 371 372 quite limited about whether the impact of environmental exposure on cardiovascular or metabolic systems may further lead to relevant comorbidities. In this study, we suggest air pollution could 373 374 increase the risk of CMM in almost a decade through multi-stage dynamics, especially for FCMD participants with IHD and participants with high genetic risk. Our results further elucidate the 375 importance of CMM prevention after long-term air pollution exposure regardless of the genetic risk, 376 especially for locations where air quality is poorer than in the UK and the burden of CMDs resulting 377 from air pollution is thus expected to be heavier. For health professionals, general practitioners, and 378 379 stakeholders, more efforts may be warranted to better protect the vulnerable population from 380 environmental risks of CMM.

381	Acknowledgments:	We thank Dr. Che	en Chen for the	language assistance.
-----	------------------	------------------	-----------------	----------------------

382

	383	Funding: I	Dr. Xu Gao	was supported	by grants	from the Pekin	ng University	(BMU2021YJ044) and
--	-----	------------	------------	---------------	-----------	----------------	---------------	--------------------

384 China CDC Key Laboratory of Environment and Population Health (2022-CKL-03).

385

386	Competing financial interests:	The authors have no	conflict of interest to disclose.
-----	---------------------------------------	---------------------	-----------------------------------

388	Data availability sta	atement: Data are	available in a p	oublic, op	en access rep	ository	7. This research
				· •			

- has been conducted using the UK Biobank Resource under Application Number 44430. The UK
- 390 Biobank data are available on application to the UK Biobank (<u>www.ukbiobank.ac.uk/</u>).

391		References
392	1.	Glynn LG. Multimorbidity: another key issue for cardiovascular medicine. Lancet.
393		2009;374(9699):1421-2.
394	2.	Prados-Torres A, Calderon-Larranaga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M.
395		Multimorbidity patterns: a systematic review. J Clin Epidemiol. 2014;67(3):254-66.
396	3.	Emerging Risk Factors C, Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, et al.
397		Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52-60.
398	4.	Atun R. Transitioning health systems for multimorbidity. Lancet. 2015;386(9995):721-2.
399	5.	Hamanaka RB, Mutlu GM. Particulate Matter Air Pollution: Effects on the Cardiovascular System.
400		Front Endocrinol (Lausanne). 2018;9:680.
401	6.	Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, et al. Particulate
402		matter air pollution and cardiovascular disease: An update to the scientific statement from the
403		American Heart Association. Circulation. 2010;121(21):2331-78.
404	7.	Yang BY, Fan S, Thiering E, Seissler J, Nowak D, Dong GH, et al. Ambient air pollution and diabetes:
405		A systematic review and meta-analysis. Environ Res. 2020;180:108817.
406	8.	Patel V, Kantipudi N, Jones G, Upton A, Kamath MV. Air Pollution and Cardiovascular Disease: A
407		Review. Crit Rev Biomed Eng. 2016;44(5):327-46.
408	9.	Tian YH, Liu H, Zhao ZL, Xiang X, Li M, Juan J, et al. Association between ambient air pollution and
409		daily hospital admissions for ischemic stroke: A nationwide time-series analysis. Plos Medicine.
410		2018;15(10).
411	10.	Ward-Caviness CK. A review of gene-by-air pollution interactions for cardiovascular disease, risk
412		factors, and biomarkers. Hum Genet. 2019;138(6):547-61.

- 413 11. Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol.
 414 2015;44(1):324-33.
- 415 12. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access
- 416 Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age.
- 417 Plos Medicine. 2015;12(3).
- 418 13. Simon RM, Subramanian J, Li MC, Menezes S. Using cross-validation to evaluate predictive accuracy
- 419 of survival risk classifiers based on high-dimensional data. Brief Bioinform. 2011;12(3):203-14.
- 420 14. Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L, et al. Sleep patterns, genetic susceptibility, and incident
- 421 cardiovascular disease: a prospective study of 385 292 UK biobank participants. Eur Heart J.

422 2020;41(11):1182-9.

- 423 15. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic data on
 424 ~500,000 UK Biobank participants. bioRxiv. 2017:166298.
- 425 16. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000
- 426 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet.
- 427 2015;47(10):1121-30.
- 428 17. Kwak SH, Park KS. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol
 429 Med. 2016;48:e220.
- 430 18. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-
- 431 wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke
- 432 subtypes. Nat Genet. 2018;50(4):524-37.
- 433 19. Wang M, Zhou T, Song Y, Li X, Ma H, Hu Y, et al. Joint exposure to various ambient air pollutants
- 434 and incident heart failure: a prospective analysis in UK Biobank. Eur Heart J. 2021.

- 435 20. Gao X, Huang N, Guo X, Huang T. Role of sleep quality in the acceleration of biological aging and its
- 436 potential for preventive interaction on air pollution insults: Findings from the UK Biobank cohort. Aging
- 437 Cell. 2022:e13610.
- 438 21. Putter H. Tutorial in biostatistics: competing risks and multi-state models. Statistics in medicine.
- 439 2007;26(11):2389-430.

74.

- 440 22. de Wreede LC. The mstate package for estimation and prediction in non- and semi-parametric multi-
- 441 state and competing risks models. Computer methods and programs in biomedicine. 2010;99(3):261-
- 442
- 443 23. Benn M, Tybjaerg-Hansen A, McCarthy MI, Jensen GB, Grande P, Nordestgaard BG. Nonfasting
- glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am
 Coll Cardiol. 2012;59(25):2356-65.
- 446 24. Han Y, Hu Y, Yu C, Guo Y, Pei P, Yang L, et al. Lifestyle, cardiometabolic disease, and multimorbidity
- in a prospective Chinese study. Eur Heart J. 2021;42(34):3374-84.
- 448 25. Singh-Manoux A, Fayosse A, Sabia S, Tabak A, Shipley M, Dugravot A, et al. Clinical,
- socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity
- 450 and mortality: A cohort study. PLoS Med. 2018;15(5):e1002571.
- 451 26. Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, et al. Guidelines for
- 452 Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. J Am
- 453 Coll Cardiol. 2022;79(18):1849-57.
- 454 27. Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, et al. Multimorbidity in Older Adults
 455 With Cardiovascular Disease. J Am Coll Cardiol. 2018;71(19):2149-61.
- 456 28. Rajagopalan S, Al-Kindi SG, Brook RD. Air Pollution and Cardiovascular Disease: JACC State-of-the-

457 Art Review. J Am Coll Cardiol. 2018;72(17):2054-70.

- 458 29. Mozaffarian D, Marfisi R, Levantesi G, Silletta MG, Tavazzi L, Tognoni G, et al. Incidence of new-
- 459 onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the
- 460 effect of clinical and lifestyle risk factors. Lancet. 2007;370(9588):667-75.
- 461 30. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet. 2011;377(9778):1693-702.
- 462 31. Saxena A, Anderson CS, Wang X, Sato S, Arima H, Chan E, et al. Prognostic Significance of
- 463 Hyperglycemia in Acute Intracerebral Hemorrhage: The INTERACT2 Study. Stroke. 2016;47(3):682-
- 464

8.

- 465 32. Dugravot A, Fayosse A, Dumurgier J, Bouillon K, Rayana TB, Schnitzler A, et al. Social inequalities in
- 466 multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II

467 cohort study. Lancet Public Health. 2020;5(1):e42-e50.

- 468 33. Canoy D, Tran J, Zottoli M, Ramakrishnan R, Hassaine A, Rao S, et al. Association between
- 469 cardiometabolic disease multimorbidity and all-cause mortality in 2 million women and men registered
- 470 in UK general practices. BMC Med. 2021;19(1):258.
- 471 34. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular
- disease: lessons learned from air pollution. Nat Rev Cardiol. 2020;17(10):656-72.
- 473 35. Dong G, Feng J, Sun F, Chen J, Zhao XM. A global overview of genetically interpretable
- 474 multimorbidities among common diseases in the UK Biobank. Genome Med. 2021;13(1):110.
- 475 36. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants
- 476 associated with coronary artery disease impair interferon-gamma signalling response. Nature.
- 477 2011;470(7333):264-8.
- 478 37. Melzer D, Pilling LC, Ferrucci L. The genetics of human ageing. Nat Rev Genet. 2020;21(2):88-101.

- 479 38. Chen R, Jiang Y, Hu J, Chen H, Li H, Meng X, et al. Hourly Air Pollutants and Acute Coronary
- 480 Syndrome Onset In 1.29 Million Patients. Circulation. 2022;0(0).
- 481 39. Zhang S, Mwiberi S, Pickford R, Breitner S, Huth C, Koenig W, et al. Longitudinal associations
- 482 between ambient air pollution and insulin sensitivity: results from the KORA cohort study. Lancet
- 483 Planet Health. 2021;5(1):e39-e49.

48	35	Figure Legends
48	36	Figure 1 Numbers (percentages) of participants in transition pattern A (solid line) and B (dashed
48	37	line) from baseline to first cardiometabolic disease (FCMD), cardiometabolic multimorbidity
48	38	(CMM), and death.
48	39	
49	90	Figure 2 Associations of five air pollutants and co-exposure score with the risks of first
49	91	cardiometabolic disease and cardiometabolic multimorbidity of pattern A using multi-state model
49	92	Models adjusted for age, sex, ethnicity, BMI, years of education, smoking status, moderate alcohol
49	93	intake, high-level physical activity, total household income, and employment status. Estimates of air
49	94	pollutants were demonstrated per $5-\mu g/m3$ increase and estimates of co-exposure score were
49	95	demonstrated per one SD increase. Dots: Point estimate; Error bar: 95% confidence limits;
49	96	
49	97	Figure 3 Graphs of the dose-response relationships of five air pollutants and co-exposure score with
49	98	the processes from baseline to FCMD and from FCMD to CMM of pattern A
49	99	Solid lines: point estimates; Shadows: 95% confidence limits;
50	00	
50	01	Figure 4 Joint associations of weighted genetic risk and air pollution levels of five transition
50)2	processes on pattern A using multi-state model
50	03	0: low GRS & 1 st quintile of co-exposure score (reference); 1: low GRS & 2 nd quintile of co-
50)4	exposure score; 2: low GRS & 3 rd quintile of co-exposure score; 3: low GRS & 4 th quintile of co-
50)5	exposure score; 4: low GRS & 5 th quintile of co-exposure score; 5: high GRS & 1 st quintile of co-
50	06	exposure score; 6: high GRS & 2 nd quintile of co-exposure score; 7: high GRS & 3 rd quintile of co-
50)7	exposure score; 8: high GRS & 4 th quintile of co-exposure score; 9: high GRS & 5 th quintile of co-
50	08	exposure score;

509	Supplementary Materials
510	Figure S1 Flowchart of participant selection
511	Figure S2 Correlation matrix of the ambient levels of five air pollutants
512	Figure S3 Graphs of the dose-response relationships of five air pollutants and co-exposure score
513	with the trajectories of cardiometabolic multimorbidity of pattern A (a: PM _{2.5} ; b: PM _{2.5-10} ; c: PM ₁₀ ; d:
514	NO ₂ , e: NO _x , f: co-exposure score)
515 516 517	Figure S4 Associations of categorical co-exposure score (quintiles) with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model Models adjusted for age, sex, ethnicity, BMI, years of education, smoking status, moderate alcohol
518	intake, high-level physical activity, total household income, and employment status.
519	
520	
521	Table S1 Characteristics of genetic variants associated with type II diabetes, ischemic heart disease,
522	and stroke
523	Table S2 Baseline characteristics of 415,855 participants by incident disease status during follow-up
524	Table S3 Associations of five air pollutants with the risks of first cardiometabolic disease,
525	cardiometabolic multimorbidity, and mortality using Cox model
526	Table S4 Associations of the co-exposure score based on $PM_{2.5}$, NO_2 , and NO_x with the trajectories
527	of cardiometabolic multimorbidity of pattern A using multi-state model
528	Table S5 Associations of air pollution with the trajectories of cardiometabolic multimorbidity of
529	pattern B using multi-state model
530	Table S6 Associations of categorical co-exposure score (quintiles) with the trajectories of
531	cardiometabolic multimorbidity of pattern B using multi-state model

- 532 **Table S7** Associations of CMD-related genetic variants with the trajectories of cardiometabolic
- 533 multimorbidity of pattern A using multi-state model (a-c) and their interactions with co-exposure

534 score (d-f)

- 535 **Table S8** Associations of weighted genetic risk score with the trajectories of cardiometabolic
- 536 multimorbidity of pattern A using multi-state model
- 537 **Table S9** Mutual associations of co-exposure score and genetic risk score with the trajectories of
- 538 cardiometabolic multimorbidity of pattern A using multi-state model in model with and without
- 539 interaction terms
- 540 Table S10 Joint associations of weighted genetic risk score and co-exposure score of five transition
- 541 states on pattern A using multi-state model
- 542 **Table S11** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of
- 543 pattern A using multi-state model additionally adjusted for baseline diet behaviors, cholesterol levels,
- and blood pressure
- 545 **Table S12** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of
- 546 pattern A using multi-state model additionally adjusted for genetic principal components
- 547 **Table S13** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of
- 548 pattern A using multi-state model in white participants
- 549 Table S14 Associations of air pollution with the trajectories of cardiometabolic multimorbidity of
- 550 pattern A using multi-state model in participants living in the baseline address for more than five

551 years

- 552 **Table S15** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of
- 553 pattern A using multi-state model by the age of having the first cardiometabolic disease



			HR (95%CI)	<i>p</i> -values				HR (95%CI)	<i>p</i> -values
PM _{2.5}					NO ₂				
Baseline→FCMD	F		1.27 (1.20, 1.34)	<0.001	Baseline→FCMD		Hel	1.01 (1.01, 1.02)	<0.001
Baseline→Death	⊢		1.29 (1.17, 1.42)	<0.001	Baseline→Death		HEH	1.03 (1.02, 1.04)	<0.001
FCMD→CMM	⊢		1.41 (1.18, 1.68)	<0.001	FCMD→CMM		⊢ ∎→i	1.04 (1.02, 1.06)	<0.001
FCMD→Death			1.35 (1.11, 1.63)	<0.001	FCMD→Death			1.05 (1.02, 1.07)	<0.001
CMM→Death	• •		0.85 (0.53, 1.36)	0.50	CMM→Death	—		1.01 (0.96, 1.08)	0.63
PM _{2.5-10}					NO _X				
Baseline→FCMD	→= -1		1.04 (0.97, 1.11)	0.27	Baseline→FCMD		-	1.01 (1.01, 1.02)	<0.001
Baseline→Death	⊢ ∎•		1.03 (0.92, 1.16)	0.57	Baseline→Death		HEH	1.02 (1.01, 1.02)	<0.001
FCMD→CMM	• •	-	1.03 (0.84, 1.27)	0.78	FCMD→CMM		HBH	1.02 (1.01, 1.03)	<0.001
FCMD→Death	• • ••		0.85 (0.67, 1.07)	0.18	FCMD→Death		H=H	1.02 (1.01, 1.04)	<0.001
CMM→Death	· · · · · · · · ·		1.10 (0.64, 1.89)	0.73	CMM→Death	—	<mark>↓</mark> ∎i	1.01 (0.98, 1.04)	0.54
PM ₁₀					Co-exposure score				
Baseline→FCMD			1.03 (0.99, 1.06)	0.11	Baseline→FCMD		HEH	1.04 (1.03, 1.06)	<0.001
Baseline→Death	HE-1		1.12 (1.06, 1.18)	<0.001	Baseline→Death		⊢ ∎→1	1.06 (1.04, 1.08)	<0.001
FCMD→CMM	•		1.10 (0.99, 1.21)	0.08	FCMD→CMM		⊢ ∎−→(1.07 (1.03, 1.11)	<0.001
FCMD→Death		-	1.14 (1.02, 1.27)	0.02	FCMD→Death			1.08 (1.04, 1.12)	<0.001
CMM→Death			1.15 (0.87, 1.51)	0.32	CMM→Death	I		1.01 (0.91, 1.11)	0.91
	0.5 0.75 1 1 Hazard Ra	.25 1.5 1.75 2 atio (95%CI)				0.9 0.95 Hazar	1 1.05 1.1 1.15 d Ratio (95%CI)		





Air pollutants	PM _{2.5}	PM _{2.5-10}	PM ₁₀	NO ₂	NOx	Co-exposure score ^a
Trajectories	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Baseline→T2D	1.47 (1.34, 1.60)	1.86 (1.12, 3.08)	1.79 (1.40, 2.30)	1.21 (1.15, 1.28)	1.12 (1.09, 1.15)	1.08 (1.06, 1.10)
Baseline→IHD	1.13 (1.04, 1.22)	0.76 (0.48, 1.21)	0.76 (0.61, 0.95)	0.98 (0.93, 1.02)	1.03 (1.00, 1.05)	1.01 (1.00, 1.03)
Baseline→Stroke	1.23 (1.02, 1.48)	1.89 (0.65, 5.51)	1.26 (0.75, 2.11)	1.04 (0.93, 1.16)	1.05 (0.98, 1.11)	1.03 (0.99, 1.08)
T2D→CMM	1.05 (1.01, 1.10)	1.01 (0.96, 1.06)	1.01 (0.99, 1.04)	1.00 (1.00, 1.01)	1.00 (1.00, 1.01)	1.05 (1.00, 1.10)
IHD→CMM	1.51 (1.08, 2.10)	0.90 (0.12, 6.56)	1.24 (0.46, 3.35)	1.28 (1.04, 1.58)	1.15 (1.04, 1.27)	1.10 (1.02, 1.18)
Stroke→CMM	1.01 (0.88, 1.15)	0.92 (0.78, 1.09)	0.98 (0.91, 1.06)	1.01 (1.00, 1.02)	1.00 (0.98, 1.01)	0.99 (0.85, 1.14)
T2D→Death	1.03 (0.97, 1.10)	0.99 (0.92, 1.07)	1.01 (0.98, 1.05)	1.00 (1.00, 1.01)	1.00 (1.00, 1.01)	1.04 (0.97, 1.11)
IHD→Death	1.10 (1.04, 1.17)	0.95 (0.88, 1.02)	1.03 (1.00, 1.07)	1.01 (1.01, 1.02)	1.01 (1.00, 1.01)	1.13 (1.06, 1.20)
Stroke→Death	1.01 (0.92, 1.10)	0.94 (0.84, 1.04)	1.01 (0.96, 1.07)	1.01 (1.00, 1.02)	1.00 (0.99, 1.01)	1.02 (0.93, 1.12)

Table 1 Associations of five air pollutants and co-exposure score with the risks of first cardiometabolic disease, cardiometabolic multimorbidity, and death after the first cardiometabolic disease of pattern B using multi-state model ^a

a: Models adjusted for age, sex, ethnicity, BMI, years of education, smoking status, moderate alcohol intake, high-level physical activity, total household income, and employment status. Estimates of air pollutants were demonstrated per $5-\mu g/m^3$ increase and estimates of co-exposure score were demonstrated per one SD increase. Bolded-values were statistically significant (*p*-values <0.05).